THTim Harloff

Tim Harloff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tim Harloff has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Repeat Ablation for Persistent Atrial Fibrillation: CFA/DOA-Guided Substrate Ablation Versus Re-PVI Alone in the Prematurely Terminated Randomized AF-CAM Trial

    by Stephan Willems, Pawel Kuklik, Peter Wohlmuth, Melanie A. Gunawardene, Jens Hartmann, Jannis Dickow, Tim Harloff, Kathrin Heitmann, Christian Meyer, Katharina Scherschel, et al.

    Background and Aims: Currently, no standard approach exists for substrate ablation in persistent atrial fibrillation (AF). This study aimed to assess whether repeat pulmonary vein isolation (Re-PVI) plus targeted substrate ablation improves long-term outcomes compared with Re-PVI alone in patients with persistent AF undergoing a second ablation. Methods: The AF-CAM study is an investigator-initiated, prospective, randomized, open-label, blinded-endpoint, multi-center clinical trial. Patients with persistent AF undergoing a second ablation for arrhythmia recurrence were randomized 1:1 to either Group A (Re-PVI alone) or Group B (Re-PVI plus targeted ablation). The primary endpoint was freedom from any atrial arrhythmia (>30 s) between 3 and 12 months of follow-up. Results: Between August 2021 and November 2023, 56 patients (mean age 68 ± 10 years, 32% women) were randomized before the trial was terminated prematurely. There was no evidence of a difference in arrhythmia recurrence between the treatment groups (hazard ratio [HR] for recurrence, Group B vs. Group A: 1.07; 95% confidence interval [CI] 0.50 to 2.33; p = 0.85). Pulmonary vein reconnection was present in 86% of patients and was not associated with the risk of atrial arrhythmia recurrence (HR 0.927, 95% CI [0.275, 3.120]). Across both groups, catheter ablation was associated with improvements in quality of life (AFEQT score) and reductions in BNP levels during follow-up. Conclusions: In this prematurely terminated randomized trial, adding CFA- and DOA-guided substrate ablation to Re-PVI did not demonstrate an improvement in freedom from atrial arrhythmia compared with Re-PVI alone. The small sample size and imprecise treatment estimate preclude a definitive conclusion about the efficacy of the adjunctive strategy. AFEQT scores increased and BNP levels decreased over follow-up in the studied patients. Larger studies are needed to further evaluate the complex atrial substrate in persistent AF.

  • Open Access

    Esophageal endoscopic findings after pulmonary vein and posterior wall isolation using pulsed field ablation: results from the Eso-PFA study

    by Melanie A Gunawardene, Melissa Middeldorp, Ulrich-Frank Pape, Sebastian Maasberg, Jens Hartmann, Jannis Dickow, Rahin Wahedi, Tim Harloff, Sophia Matuschka, Arian Sultan, et al.

    Aims: Substrate modification, including left atrial posterior wall isolation (LAPWI), may be performed in AF patients undergoing catheter ablation. Pulsed field ablation (PFA) may protect adjacent structures like the esophagus. However, data on esophageal safety following PFA-guided LAPWI are limited. The aim is to evaluate esophageal safety during post-procedural esophagogastroduodenoscopy (EGD) and follow-up after PFA-guided LAPWI in patients with AF. Methods and results: This prospective observational study included consecutive AF patients who underwent PFA-guided LAPWI and post-procedural EGD (the day after PFA), with follow-up for long-term safety. In total, 106 consecutive patients (94% persistent AF, 66 ± 14 years, 70% male, 2 ± 1 prior ablation procedures) were included. The total median procedure time was 78 [interquartile range (IQR): 49–111] min, and a mean of 50 ± 19 and 21 ± 9 PFA applications were delivered per patient and on the LAPW, respectively. One suspected transient ischaemic attack and three minor complications occurred. No thermal, ablation-related esophageal lesions were observed in any patient during EGD. Non-ablation-related incidental gastrointestinal findings were detected in 70% of patients. During a median follow-up of 606 days [IQR: 212–922], no additional esophageal adverse events were reported. Atrial arrhythmia recurrences occurred in 34% (36/106) patients (including antiarrhythmic drugs). Left atrial posterior wall isolation durability was 78% (11/14). Conclusion: In this real-world cohort, PFA-guided LAPWI was safe for the esophagus, with no thermal injury observed in post-procedural endoscopy. These results further support PFA as a promising technology for AF ablation with a favourable esophageal safety profile. The role of post-ablation proton pump inhibitors in a population where incidental gastrointestinal findings were common needs further exploration.


  • Open Access

    Contemporary catheter ablation of complex atrial tachycardias after prior atrial fibrillation ablation: pulsed field vs. radiofrequency current energy ablation guided by high-density mapping

    by Melanie A Gunawardene, Tim Harloff, Mario Jularic, Jannis Dickow, Rahin Wahedi, Omar Anwar, Peter Wohlmuth, Nele Gessler, Jens Hartmann, Stephan Willems

    Catheter ablation (CA) of post-ablation left atrial tachycardias (LATs) can be challenging. So far, pulsed field ablation (PFA) has not been compared to standard point-by-point radiofrequency current (RFC) energy for LAT ablation. To compare efficacy of PFA vs. RFC in patients undergoing CA for LAT. Consecutive patients undergoing LAT-CA were prospectively enrolled (09/2021–02/2023). After electro-anatomical high-density mapping, ablation with either a pentaspline PFA catheter or RFC was performed. Patients were matched 1:1. Ablation was performed at the assumed critical isthmus site with additional ablation, if necessary. Right atrial tachycardia (RAT) was ablated with RFC. Acute and chronic success were assessed. Fifty-six patients (n = 28 each group, age 70 ± 9 years, 75% male) were enrolled. A total of 77 AT (n = 67 LAT, n = 10 RAT; 77% macroreentries) occurred with n = 32 LAT in the PFA group and n = 35 LAT in the RFC group. Of all LAT, 94% (PFA group) vs. 91% (RFC group) successfully terminated to sinus rhythm or another AT during ablation (P = 1.0). Procedure times were shorter (PFA: 121 ± 41 vs. RFC: 190 ± 44 min, P < 0.0001) and fluoroscopy times longer in the PFA group (PFA: 15 ± 9 vs. RFC: 11 ± 6 min, P = 0.04). There were no major complications. After one-year follow-up, estimated arrhythmia free survival was 63% (PFA group) and 87% (RFC group), [hazard ratio 2.91 (95% CI: 1.11–7.65), P = 0.0473]. Pulsed field ablation of post-ablation LAT using a pentaspline catheter is feasible, safe, and faster but less effective compared to standard RFC ablation after one year of follow-up. Future catheter designs and optimization of the electrical field may further improve practicability and efficacy of PFA for LAT.